Alnylam Pharmaceuticals Inc. (ALNY) News

Alnylam Pharmaceuticals Inc. (ALNY): $189.98

-0.51 (-0.27%)

POWR Rating

Component Grades













Add ALNY to Watchlist
Sign Up

Industry: Biotech


of 382

in industry

Filter ALNY News Items

ALNY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALNY News Highlights

  • ALNY's 30 day story count now stands at 9.
  • Over the past 25 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ALNY are HALO and RNA.

Latest ALNY News From Around the Web

Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam CEO Yvonne Greenstreet sees growing the company as 'a wonderful challenge'

When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.

Yahoo | March 21, 2023

Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | March 21, 2023

3 Growth Stocks That Could Disrupt the Healthcare Industry

These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.

Alex Sirois on InvestorPlace | March 13, 2023

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.

Yahoo | March 9, 2023

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

CAMBRIDGE, Mass., March 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.

Yahoo | March 8, 2023

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

CAMBRIDGE, Mass., March 01, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

Yahoo | March 1, 2023

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder today’s conference call is being recorded. I would now like to turn the conference over to the company. Please go ahead. […]

Yahoo | February 25, 2023

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future

We feel now is a pretty good time to analyse Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) business as it appears the...

Yahoo | February 25, 2023

Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.

Yahoo | February 24, 2023

Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7784 seconds.